Researchers at the Indian Institute of Science and the Technical University of Denmark have developed a recombinant, nanobody-based antivenom that neutralizes venom from geographically diverse cobra and king cobra species in India, according to a study published in Science Translational Medicine. India reports nearly 50,000 snakebite deaths every year, representing the highest mortality toll from snakebites worldwide.
The Limitations of Conventional Animal-Derived Antivenoms
Snakebite remains a neglected tropical disease responsible for hundreds of thousands of annual deaths and permanent disabilities. Each snake species produces a distinct cocktail of toxins targeting nerves, blood, or tissues, which complicates the development of unified treatments. Traditional antivenoms rely on animal immunization and venom milking, a production method that has remained largely unchanged for over 100 years, according to Kartik Sunagar, an associate professor at the Centre for Ecological Sciences at the Indian Institute of Science.
“Antivenom treatment has virtually not changed for over 100 years,” Sunagar states, noting that these conventional products suffer from batch-to-batch variability, severe side effects, limited species coverage, high costs, and low active antibody yields.
Did you know? Traditional antivenom manufacturing involves immunizing animals like horses, a process that can cause adverse side effects in patients and results in significant batch variability.
Engineering Recombinant Nanobodies for Broad Protection
To overcome the limitations of horse-derived antivenoms, researchers engineered recombinant antibodies using microbial and humanized expression systems. Andreas Laustsen, a professor at the Technical University of Denmark, collaborated with Sunagar on the project. The research builds on earlier work where scientists immunized camelids—such as alpacas and llamas—with African snake venoms, extracted the resulting antibodies, and mass-produced them using microbial cells.
The team displayed these antibodies on bacteriophages, exposed them to various snake venoms, and isolated specific antibody fragments capable of binding to and neutralizing toxins. Specifically, the researchers isolated a cocktail of five nanobodies derived from the tip of light-chain protein regions. This cocktail successfully binds to toxins across multiple cobra species and prevents the venom from attaching to its target receptors.
Laboratory Testing and Efficacy in Animal Models
When tested in mice injected with venom, the antibody cocktail provided broad protection against spectacled cobras, monocled cobras, and both Indian king cobra species. According to the researchers, the treatment successfully saved mice from death even when administered 30 minutes after venom injection.
“Even mice that were paralysed or had typical neurotoxic symptoms would revert to a completely asymptomatic state,” Sunagar explains.
Previous efforts often required large amounts of monoclonal antibodies to neutralize snake venom in laboratory models, raising questions about human dosing requirements. The research team demonstrated that very small amounts of carefully engineered antibodies could effectively neutralize venom, which may help address cost and safety concerns associated with administering large quantities of traditional antibodies, according to Sunagar.
Pro Tip: Future recombinant antivenoms can be tailored for different global regions by adding supplementary antibody components to target the specific toxin families driving disease locally, as noted by the study’s authors.
Interdisciplinary Collaboration in Toxinology
Addressing a global health challenge of this scale required combining expertise across multiple scientific disciplines and countries. Anne Ljungars, a senior researcher at the Technical University of Denmark and co-author of the study, emphasizes that solving the snakebite crisis demands joint efforts in toxinology, antibody engineering, and protein science.
“This work provides a blueprint for how recombinant antivenoms can be tailored to different regions of the world by targeting the toxin families that drive disease in local snake species,” Laustsen says.
Frequently Asked Questions
What makes traditional antivenom production difficult?
Traditional antivenom relies on animal immunization and venom milking, resulting in low active antibody yields, high production costs, batch-to-batch variability, and limited species coverage.
How do nanobody-based antivenoms differ from conventional treatments?
Nanobody-based antivenoms use recombinant antibodies manufactured through microbial and humanized expression systems, eliminating the need to repeatedly immunize animals like horses.
Which snake species are covered by this new nanobody cocktail?
The newly developed nanobody cocktail protects against venom from spectacled cobras, monocled cobras, and Indian king cobra species.
Can these recombinant antivenoms be adapted for other regions?
Yes. Additional antibody components can be integrated into the platform to target medically important snakes in other geographic areas.
Explore More: Want to stay updated on breakthrough medical research and global health developments? Subscribe to our newsletter or leave a comment below to share your thoughts on the future of snakebite treatments.
Worth a look